It is a totally new test for prostate cancer. The test works by measuring the minute changes in the composition of a person's prostate secretion or seminal fluid that are caused by cancer. In order to establish whether the prostate is healthy or not, the previously measured values of the biomarkers that we have developed at CAMONX are combined into an index, which indicates the presence of the disease.
Cambridge Oncometrix has discovered and quantified a panel of substances (biomarkers) present in the prostatic gland, which change when affected by a malignant transformation. A set of non-protein biomarkers has been identified by making a direct comparison of carefully characterized prostate tissue samples taken from:
• 35 healthy men
• 45 men with Benign Prostatic Hyperplasia
• 60 men with Prostate Cancer
This term refers to the secretion of the prostatic gland, which can be found in various different sources such as expressed prostatic secretion and in ejaculate. Whereas ejaculate can be produced at home and consequently analyzed by a home test, prostatic secretions are taken for analysis by a urologist or GP.
Using our CAMONX markers Cambridge Oncometrix aims to develop two types of prostate cancer test: a non-invasive home test for patients and a clinical test for medical professionals using a bench top analyzer in their clinic or laboratory. We estimate that it will take about 3-5 years to finish the clinical trials and obtain regulatory approvals.
Cambridge Oncometrix is currently conducting a small-scale proof-of-concept clinical trial using samples that are sourced from abroad. However, in 2016 we plan to start a clinical trial in the UK.
Yes. You can register your interest to participate in the planned UK study on our web page. You can also participate in the current clinical investigation. To do so you will need to travel to our clinical trial centre in St. Petersburg. However, we would not be able to reimburse you your travel and accommodation costs in Russia.
No. Needle biopsy remains the ‘gold standard’ diagnostic test for prostate cancer and will not be replaced by the CAMONX test any time soon. However, once approved the CAMONX test should be able to help you to decide whether or not you need to undergo a biopsy.
It is unknown yet. There are some indications that there is a correlation between the CAMONX markers and the aggressiveness of the tumor. We believe that our test will help patients and doctors to be able to identify who will benefit from prostate cancer treatment.
Cambridge Oncometrix has filed a patent application on 45 prostate cancer biomarkers. Further patents are foreseen to cover the specific designs of the prophylactic and diagnostic devices.